Coronil Not Covid-19 Cure, Rules Delhi High Court As Ramdev Ordered To Withdraw Claims
The Delhi High Court observed that Coronil is not a cure for Covid-19, but rather a safety measure or an immunity booster, on Monday.
The court directed Baba Ramdev and Acharya Balkrishna to retract the statements they made against allopathy and on Coronil in three days. If they fail to remove these statements from their social media sites within the given time, the social media platforms will take down the content on their own.
The single judge bench of the high court, comprising Justice Anup Jairam Bhambhani, has further asked Ramdev not to make any more such statements.
While Ramdev and his party advertised their product, Coronil, as a cure for the pandemic-causing virus, the licenses that it received from the competent authorities were only as a safety measure from Covid or an immunity booster at best, the court observed.
For clarity, the single judge bench also considered the findings of the Supreme Court in the case Indian Medical Association & Anr. vs. Union of India. This case involved accusations against Ramdev and the party for publishing misleading advertisements about the medicinal benefits of their products. The apex court has made several strict observations and remarks against Ramdev in the matter.
While the court usually wouldn't address issues pending before the Supreme Court, the apex court has stated that its ongoing review does not prevent further proceedings in this case, Justice Bhambhani said.
On Feb. 19, 2021, Baba Ramdev posted a tweet announcing 'Coronil' as an evidence-based medicine for Covid-19. He claimed that it was a significant breakthrough in the fight against the virus. On the same day, a video was uploaded on News18 India's YouTube channel featuring Baba Ramdev. In the video, he discussed how 'Coronil' had saved numerous lives, further promoting it as an effective treatment for Covid-19.
Additional tweets from Patanjali Dairy emphasised that 'Coronil' was a cure for Covid-19. They repeatedly asserted the product's effectiveness, positioning it as a reliable treatment option. Another set of tweets involved disparaging statements against allopathy.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.